Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pyxis Oncology Inc PYXS

Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes PYX-201, PYX-106 and PYX-107. PYX-201, an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin within the tumor stroma... see more

Recent & Breaking News (NDAQ:PYXS)

Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201

GlobeNewswire 2 days ago

Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data

GlobeNewswire November 20, 2024

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024

GlobeNewswire November 12, 2024

Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201

GlobeNewswire November 11, 2024

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS)

PR Newswire September 25, 2024

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

GlobeNewswire August 29, 2024

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024

GlobeNewswire August 14, 2024

Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference

GlobeNewswire July 29, 2024

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 28, 2024

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

GlobeNewswire June 10, 2024

Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

GlobeNewswire May 30, 2024

Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

GlobeNewswire May 14, 2024

Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference

GlobeNewswire May 9, 2024

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 28, 2024

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

GlobeNewswire March 27, 2024

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023

GlobeNewswire March 21, 2024

Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

GlobeNewswire March 13, 2024

Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024

GlobeNewswire March 7, 2024

Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting

GlobeNewswire March 5, 2024

Pyxis Oncology Announces $50 Million Private Placement

GlobeNewswire February 27, 2024